Dihexa, an unapproved research chemical derived from a blood-pressure hormone and used for sharper memory, has never been tested directly in people. Evidence comes from cell and animal studies, mostly by its inventors, three of whose papers were withdrawn for falsified or fabricated data. A human trial of an injectable relative found no meaningful memory benefit in Alzheimer's disease. Safety is largely unknown, with tumor growth the central theoretical concern. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Eosinophil count (CBC) | 0–500 cells/µL | Safety check: rose with a related compound |
| ALT and AST | ALT 7–56 U/L; AST 10–40 U/L | Safety check: human liver effects unknown |
| Serum creatinine | 0.6–1.3 mg/dL | Safety check: elimination route unknown |
| Cognitive test score (MoCA or computerized battery) | No established target; track change from own baseline | Marker expected to change |
| Home blood pressure | Not specified in the ER | Human blood-pressure effects unstudied |
Cadence: Baseline before starting (two cognitive baselines), repeated at 4 weeks and at the planned trial end (commonly 8 weeks), then every 3 months if use continues; cognitive testing at the same time of day and under similar sleep conditions